Professional Marketing briefs

Share this article:
Abbott announced that it will cut 1,900 positions in a restructuring exercise intended to streamline commercial and manufacturing operations. Sales jobs are one of the target areas for the cuts, according to Scott Stoffel, and Abbott spokesperson. The cost-cutting measures will take place “primarily in the US,” said Stoffel. Miles White, chairman and CEO at Abbott, cited European pricing pressures and a regulatory environment that “says no more than it says yes,” as reasons for the cuts.

Aqua Pharmaceuticals appointed Ted White to VP, sales. White's responsibilities include managing Aqua's “rapidly growing sales force,” according to a company announcement. White joins Aqua from Novartis, where he worked as managing director. Aqua is a specialty pharma focused on dermatology products.

Clinical Data will launch Viibryd, a depression medication, during the second quarter of 2011. The brand received FDA approval on January 21, and 150 sales reps will target psychiatrists and high-prescribing primary care physicians at launch, Drew Fromkin, CEO and president at Clinical Data, told MM&M. Clinical Data reps will “more likely…focus on the specialty psychiatry side, and hope to expand through other relationships on the primary care side,” said Fromkin.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.